enpp-1

Enpp-1-IN-14 is a potent inhibitor of Ectonucleotide Pyrophosphatase Phosphodiesterase-1 (ENPP1) with an IC50 value of 32.38 nM for recombinant human ENPP-1. Enpp-1-IN-14 has anti-tumor activity.

Enpp-1-IN-16 is an inhibitor targeting ENPP1 with potential anti-cancer activity.Enpp-1-IN-16 can be used to study insulin resistance in relation to type II diabetes mellitus and various ENPP1-mediated diseases in the chondrocalcinosis and osteoarthritis classes.

Enpp-1-IN-6 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) with potential applications in cancer and infectious disease research.

Enpp-1-IN-10 (compound 1) is a potent inhibitor of Ecto-nucleotide pyrophosphatase phosphodiesterases 1 (ENPP1) with a Ki value of 3.866 μM, suitable for anticancer research [1].

Enpp-1-IN-13 is an ectonucleotide pyrophosphatase phosphodiesterase (ENPP) inhibitor that is able to act on ENPP1 (IC50: 1.29 μM) and ENPP3 (IC50: 20.2 μM), exhibiting anticancer effects.

Enpp-1-IN-21 (compound 4g) is an inhibitor of ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1), with IC50 values of 0.45 μM for ENPP1 and 0.19 μM for ENPP3.

Enpp-1-IN-25 (Compound 30) is an ENPP1 inhibitor with an IC50 of 8.05 nM and exhibits low oral bioavailability. By inhibiting cGAMP degradation, it effectively activates the intracellular STING pathway. Enpp-1-IN-25 can enhance immune cell infiltration and type I interferon response in the tumor microenvironment, thereby increasing the antitumor efficacy of anti-PD-L1 antibodies. It is applicable for research in cancer immunotherapy.

Enpp-1-IN-8 is a potent ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP-1) inhibitor with broad specificity, capable of cleaving a wide range of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds of nucleotides and nucleotide sugars. Enpp-1-IN-8 shows potential for cancer and infectious disease studies.

Enpp-1-IN-11 (compound 23) is a highly potent inhibitor of Ecto-nucleotide pyrophosphatase phosphodiesterases 1 (ENPP1), with a Ki value of 45 nM. It demonstrates excellent stability in human and mouse plasma and exhibits low clearance in both human and mouse liver microsomes, holding promise for anticancer research [1].

Enpp-1-IN-4 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) with potential for cancer disease studies.

Enpp-1-IN-5 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1), which exhibits broad specificity, capable of cleaving phosphodiester bonds of nucleotides and nucleotides, as well as pyrophosphate bonds of nucleotides and nucleotides. Enpp-1-IN-5 has potential applications in cancer and infectious disease research.

Enpp-1-IN-22 is a potent oral bioavailable prodrug of the ENPP1 inhibitor dimeric paraformaldehyde ester, exhibiting anticancer activity.

Compound 88a (Enpp-1-IN-15) is an inhibitor of Ectonucleotide Pyrophosphatase Phosphodiesterase 1 (Enpp-1), exhibiting a Ki value of 0.00586 nM [1].

Enpp-1-IN-19 (compound 29f) is an orally active inhibitor of ENPP1 that effectively blocks cGAMP hydrolysis with an IC50 of 68 nM. It not only enhances anti-PD-L1 responses and curtails tumor growth in CT26 syngeneic models but also boosts STING-mediated type I interferon responses. Additionally, Enpp-1-IN-19 fosters immune memory and aids in preventing tumor recurrence [1].

Enpp-1-IN-24 (compound 7) is an ENPP1 inhibitor that, when used in combination with anti-PD-1 antibodies, achieves a tumor growth inhibition rate of 77.7% and enhances survival rates in a mouse model.

Enpp-1-IN-9, a powerful inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP1), exhibits wide substrate specificity, capable of cleaving various bonds such as phosphodiester bonds of nucleotides and nucleotide sugars, as well as pyrophosphate bonds of nucleotides and nucleotide sugars. Its potential application lies in the fields of cancer and infectious disease research[1].

Enpp-1-IN-23 (compound 27) is an Enpp-1 inhibitor with an IC50 value of 1.2 nM. This compound is utilized in cancer research.

Enpp-1-IN-1 is an inhibitor of Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1)

Enpp-1-IN-17 (example 274) is a potent inhibitor of ENPP1, with inhibition constants (Ki values) ranging from 100 nM to 1 μM for cGAMP hydrolysis and greater than 1 μM for ATP hydrolysis, demonstrating a selectivity ratio of over 6.4 favoring cGAMP hydrolysis inhibition [1].

Enpp-1-IN-12 (compound 43), an orally active and potent inhibitor of ecto-nucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) with a K_i of 41 nM, exhibits anti-tumor activity [1].

Enpp-1-IN-7 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1), which has broad specificity and cleaves a wide range of substrates, including phosphodiester bonds and pyrophosphate bonds of nucleotides and nucleotides. Enpp-1-IN-7 has potential applications in cancer and infectious disease research.

Enpp Carbonic anhydrase-IN-1 (compound 1e) is a potent inhibitor of Enpp and carbonic anhydrase, exhibiting IC50s of 1.36, 1.35, 3.00, 0.88, and 1.02 µM for NPP1, NPP2, NPP3, CA-II, and CA-IX respectively. Enpp Carbonic anhydrase-IN-1 also demonstrates selective antiproliferative activity for cancer cells.

Enpp Carbonic anhydrase-IN-2 is a potent Enpp and carbonic anhydrase inhibitor with IC 50 s of 1.13, 1.07, 0.74, 0.33, 0.68 for NPP1, NPP2, NPP3, CA-IX, CA-XII respectively. Enpp Carbonic anhydrase-IN-2 shows antiproliferative activity for cancer cells and low cytotoxic against normal cells. Enpp Carbonic anhydrase-IN-2 induces Apoptosis .

ENPP1 Inhibitor C is an ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) inhibitor with potential anticancer activity for the study of triple-negative breast cancer.